Literature DB >> 26263125

Binding Kinetics versus Affinities in BRD4 Inhibition.

Ming Kuang1,2, Jingwei Zhou2, Laiyou Wang1, Zhihong Liu2, Jiao Guo1, Ruibo Wu2.   

Abstract

Bromodomains (BRDs) are protein modules that selectively recognize histones as a "reader" by binding to an acetylated lysine substrate. The human BRD4 has emerged as a promising drug target for a number of disease pathways, and several potent BRD inhibitors have been discovered experimentally recently. However, the detailed inhibition mechanism especially for the inhibitor binding kinetics is not clear. Herein, by employing classical molecular dynamics (MD) and state-of-the-art density functional QM/MM MD simulations, the dynamic characteristics of ZA-loop in BRD4 are revealed. And then the correlation between binding pocket size and ZA-loop motion is elucidated. Moreover, our simulations found that the compound (-)-JQ1 could be accommodated reasonably in thermodynamics whereas it is infeasible in binding kinetics against BRD4. Its racemate (+)-JQ1 proved to be both thermodynamically reasonable and kinetically achievable against BRD4, which could explain the previous experimental results that (+)-JQ1 shows a high inhibitory effect toward BRD4 (IC50 is 77 nM) while (-)-JQ1 is inactive (>10 μM). Furthermore, the L92/L94/Y97 in the ZA-loop and Asn140 in the BC-loop are identified to be critical residues in (+)-JQ1 binding/releasing kinetics. All these findings shed light on further selective inhibitor design toward BRD family, by exploiting the non-negligible ligand binding kinetics features and flexible ZA-loop motions of BRD, instead of only the static ligand-protein binding affinity.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26263125     DOI: 10.1021/acs.jcim.5b00265

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  7 in total

1.  Bisphosphonate-Functionalized Hydroxyapatite Nanoparticles for the Delivery of the Bromodomain Inhibitor JQ1 in the Treatment of Osteosarcoma.

Authors:  Victoria M Wu; Jarrett Mickens; Vuk Uskoković
Journal:  ACS Appl Mater Interfaces       Date:  2017-07-28       Impact factor: 9.229

Review 2.  Recent progress on cheminformatics approaches to epigenetic drug discovery.

Authors:  Zoe Sessions; Norberto Sánchez-Cruz; Fernando D Prieto-Martínez; Vinicius M Alves; Hudson P Santos; Eugene Muratov; Alexander Tropsha; José L Medina-Franco
Journal:  Drug Discov Today       Date:  2020-09-30       Impact factor: 7.851

3.  In silico design and molecular basis for the selectivity of Olinone toward the first over the second bromodomain of BRD4.

Authors:  Yoel Rodríguez; Guillermo Gerona-Navarro; Roman Osman; Ming-Ming Zhou
Journal:  Proteins       Date:  2019-10-21

4.  Selective inhibition mechanism of RVX-208 to the second bromodomain of bromo and extraterminal proteins: insight from microsecond molecular dynamics simulations.

Authors:  Qianqian Wang; Ying Li; Jiahui Xu; Yuwei Wang; Elaine Lai-Han Leung; Liang Liu; Xiaojun Yao
Journal:  Sci Rep       Date:  2017-08-18       Impact factor: 4.379

5.  Mechanistic Analysis of Chemically Diverse Bromodomain-4 Inhibitors Using Balanced QSAR Analysis and Supported by X-ray Resolved Crystal Structures.

Authors:  Magdi E A Zaki; Sami A Al-Hussain; Aamal A Al-Mutairi; Vijay H Masand; Abdul Samad; Rahul D Jawarkar
Journal:  Pharmaceuticals (Basel)       Date:  2022-06-14

6.  Attach-Pull-Release Calculations of Ligand Binding and Conformational Changes on the First BRD4 Bromodomain.

Authors:  Germano Heinzelmann; Niel M Henriksen; Michael K Gilson
Journal:  J Chem Theory Comput       Date:  2017-06-13       Impact factor: 6.006

7.  BRD4 as a therapeutic target for nonfunctioning and growth hormone pituitary adenoma.

Authors:  Chengzhang Shi; Zhao Ye; Jie Han; Xiaoqing Ye; Wenchao Lu; Chenxing Ji; Zizhou Li; Zengyi Ma; Qilin Zhang; Yichao Zhang; Wenqiang He; Zhengyuan Chen; Xiaoyun Cao; Xuefei Shou; Xiang Zhou; Yongfei Wang; Zhaoyun Zhang; Yiming Li; Hongying Ye; Min He; Hong Chen; Haixia Cheng; Jun Sun; Jianyong Cai; Chuanxin Huang; Fei Ye; Cheng Luo; Bing Zhou; Hong Ding; Yao Zhao
Journal:  Neuro Oncol       Date:  2020-08-17       Impact factor: 12.300

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.